EndometriomaESCOMANCT06955221
Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis
A study testing Ultrasound-guided aspiration and alcohol sclerotherapy in people with Endometrioma and Ultrasound Therapy; Complications, run by Hospital Universitari de Bellvitge at 27 sites in Spain.
Trial summary
The goal of this clinical trial is to evaluate whether ultrasound-guided alcohol sclerotherapy can improve pelvic pain and quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas, compared to expectant management. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Endometrioma, Ultrasound Therapy; Complications, Quality of Life
- What is being tested?
- Ultrasound-guided aspiration and alcohol sclerotherapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 288 participants
- Where
- 27 sitesSpain
- Study dates
- 1 Jan 2025to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Female sex
- Age ≥18 and ≤45 years
- Ultrasound suspicion of unilocular endometrioma or with a thin septum less than 3 mm
- Size between 30-100 mm, persistent for at least 3-6 months since diagnosis
- Ca125 marker <300 UI/mL and HE4 < 70 pM
- Signed informed consent
Who cannot join
- Age <18 or >45 years
- History of ovarian or uterine cancer
- Endometrioma size <30 mm or >100 mm
- Indication for surgical treatment of the endometrioma due to suspected severe extra-ovarian endometriosis or any other cause
- Ultrasound suspicion of dermoid cysts, anechoic cysts, or cysts with high risk of malignancy
- Ca125 >300 UI/mL
Show all 9Show fewer
- HE4 >70 pM
- Pregnant women
- Patients who do not wish to participate in the study or who are mentally incapacitated
Trial locations and contacts
27 sites in 1 country. Contact the study team or a site near you to ask about taking part.
27 sites in 1 country
Spain27 sites, 27 recruiting
- Not yet recruiting
Hospital Universitario Germans Trias i Pujol
Badalona, Barcelona, 08916
Sara Iglesias, siglesiasf.mn.ics@gencat.cat
Sara Iglesias
- Recruiting
Hospital del Mar
Barcelona, 08003
Mauricio Agüero, maguero@psmar.cat
Mauricio Agüero
- Not yet recruiting
Hospital Universitario de Burgos
Burgos, 09006
Irene Gonzalo García, igonzalo@saludcastillayleon.es
Irene Gonzalo García
- Not yet recruiting
Hospital de la Vega Lorenzo Guirao
Cieza, Murcia, 30530
Esperanza Gadea Niñoles, egn-75@hotmail.com
Esperanza Gadea Niñoles
- Not yet recruiting
Clínica Sanabria
Granada, 18012
Macarena Ríos Lorenzo, macarenarios21@gmail.com
Macarena Ríos Lorenzo
- Recruiting
Consorci Sanitari de l'Anoia
Igualada, Barcelona, 08700
Jennifer Rovira, jrovira@csa.cat
Jennifer Rovira
- Not yet recruiting
Hospital Universitario de Jaén
Jaén, 23007
Antonio Carballo García, antonio.gine@gmail.com
Antonio Carballo García
- Recruiting
Consorci Sanitari Integral
L'Hospitalet de Llobregat, Barcelona, 08906
Marta Castellarnau, yembe10@yahoo.es
Marta Castellarnau
- Recruiting
Hospital Universitario de Bellvitge
L'Hospitalet de Llobregat, Barcelona, 08907
Amparo Garcia-Tejedor, agarciat@bellvitgehospital.cat
Amparo Garcia-Tejedor
- Not yet recruiting
Hospital Universitario Arnau de Vilanova
Lleida, 25198
Núria Muñiz López, nmuniz.lleida.ics@gencat.cat
Núria Muñiz López
- Not yet recruiting
Hospital Universitario San Pedro
Logroño, La Rioja, 26006
María Carmen Salvador Ballada, csalvador@riojasalud.es
María Carmen Salvador Ballada
- Recruiting
Hospital Universitario Ramón y Cajal
Madrid, 28034
Irene Pelayo Delgado, irene.pelayo@salud.madrid.org
Irene Pelayo Delgado
- Recruiting
Hospital Clínico San Carlos
Madrid, 28040
Ignacio Cristóbal Quevedo, icristobal@salud.madrid.org
Ignacio Cristóbal Quevedo
- Recruiting
Hospital Universitario 12 de Octubre
Madrid, 28041
Gregorio López González, goyolopez2@hotmail.com
Gregorio López González
- Not yet recruiting
Hospital San Juan de Dios de Martorell
Martorell, Barcelona, 08760
Ángel Toro, atoro@hmartorell.cat
Ángel Toro
- Not yet recruiting
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, 07210
Ana Belén Castel Segui, anab.castel@ssib.es
Ana Belén Castel Segui
- Not yet recruiting
Hospital Universitari Sant Joan de Reus
Reus, Tarragona, 43204
Rosa Pedro Carulla, rosa.pedro.carulla@gmail.com
Rosa Pedro Carulla
- Not yet recruiting
Consorci Corporació Sanitària Parc Taulí
Sabadell, Barcelona, 08208
Laura Costa, LCOSTA@tauli.cat
Laura Costa
- Not yet recruiting
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320
Ana Isabel Padilla Pérez, apadillp@ull.edu.es
Ana Isabel Padilla Pérez
- Recruiting
Hospital General Universitario Los Arcos del Mar Menor
San Javier, Murcia, 30739
Shiana Corbalán, shiana.corbalan@gmail.com
Shiana Corbalán
- Not yet recruiting
Parc Sanitari Sant Joan de Deu
Sant Boi de Llobregat, Barcelona, 08830
Manel Carreras, manuel.carreras@sjd.es
Manel Carreras
- Not yet recruiting
Hospital Universitario Joan XXIII
Tarragona, 43005
María Gómez Romero, mariagomez8@gmail.com
María Gómez Romero
- Not yet recruiting
Consorcio Hospital General Universitario de València
Valencia, 46014
Susana Royo, draroyo.s@gmail.com
Susana Royo
- Recruiting
Hospital Recoletas Salud Campo Grande
Valladolid, 47007
Isabel Gippini, isabel.gippini@gruporecoletas.com
Isabel Gippini
- Recruiting
Hospital de Viladecans
Viladecans, Barcelona, 08840
Cristina Molinet, cmolinet.hv@gencat.cat
Cristina Molinet
- Not yet recruiting
Hospital Universitario de Álava - Txagorritxu
Vitoria-Gasteiz, Álava, 01009
Janire González, janire.gonzalezcalvino@osakidetza.eus
Janire González
- Not yet recruiting
Hospital Clínico Universitario Lozano Blesa
Zaragoza, 50009
Ana Cristina Lou, dra.aclou@gmail.com
Ana Cristina Lou
About this study
Official title: Effect of US-guided Alcohol Sclerotherapy for Endometriomas on Pelvic Pain and Quality of Life
The goal of this clinical trial is to evaluate whether ultrasound-guided alcohol sclerotherapy can improve pelvic pain and quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas, compared to expectant management.
The main questions it aims to answer are:
Read more
- - Does sclerotherapy significantly reduce pelvic pain compared to expectant management?
- - Does sclerotherapy improve quality of life as measured by the EHP-5 score?
Researchers will compare the sclerotherapy group to the expectant management group to determine whether the intervention leads to greater improvement in pain and quality of life.
Participants will:
- Be randomly assigned to one of two groups: (1) Sclerotherapy group: undergo ultrasound-guided puncture and alcohol sclerotherapy; (2) Control group: expectant management
- Complete quality of life and pain assessments at baseline and after 6 months
- Provide blood and urine samples for biomarker analysis (e.g., cortisol, IL-6, hsCRP, catecholamines)
- Undergo ovarian reserve assessments (AMH, antral follicle count)
- Be followed for adverse events, recurrence, fertility outcomes, and treatment-related costs
The study will follow an intention-to-treat and per-protocol analysis approach.
Read the detailed description
Endometriosis is a chronic gynecological disease that affects women of reproductive age, characterized by the abnormal growth of endometrial tissue outside the uterine cavity.
It affects 5-10% of women of reproductive age (Becker et al., 2022) and is associated with infertility in 40% of cases (Coccia et al., 2008). Among its clinical forms, ovarian endometrioma is the most frequent, appearing in 15-45% of patients with endometriosis (Cranney et al., 2017). In addition to its impact on fertility, the main clinical manifestation of endometriosis is pain. Chronic pelvic pain caused by endometriosis can be disabling and even lead to work absenteeism, with a significant impact on the quality of life of affected patients, who often experience delayed diagnosis, making its management even more difficult and requiring a multidisciplinary approach (Horne \& Missmer, 2022).
Currently, there is still no consensus on what should be the first-line treatment for ovarian endometrioma (Gordts \& Campo, 2019). However, cystectomy reduces ovarian reserve due to the removal of healthy ovarian tissue adjacent to the cyst wall-something that further worsens the reproductive prognosis in patients whose fertility is already diminished due to endometriosis per se (Alborzi et al., 2021; Martinez-Garcia et al., 2021). Moreover, despite surgical removal of the endometrioma, the recurrence rate is high, ranging from 15-30% (Jee, 2022).
In recent years, there has been a shift toward more conservative treatments for the management of endometrioma, such as expectant management or aspiration and sclerosis (Garcia-Tejedor et al., 2020). Various authors have shown that ultrasound-guided aspiration and alcohol sclerosis may be a promising option, as concluded in the meta-analysis by Cohen et al., which found that recurrence rates were similar to those of laparoscopic management of ovarian endometrioma, but with fewer complications. Results in assisted reproductive technology are also better compared to surgical treatment in symptomatic women, particularly in those with low ovarian reserve (Zhang et al., 2022). Furthermore, other comparative studies between surgery and aspiration-sclerosis have shown that, although recurrence rates are similar, pregnancy rates are higher in patients treated with sclerosis, with the same complication rate and significantly lower costs (Garcia-Tejedor et al., 2020; Zhang et al., 2022).
Currently, the first-line treatment in patients diagnosed with endometriosis is hormonal therapy through the use of hormonal contraceptives. However, its efficacy in managing endometrioma is lower, and therefore, there is no consensus on its indication for this specific form of endometriosis (Cranney et al., 2017). In patients with a desire for pregnancy, alternative approaches are sought that do not interfere with fertility. At present, this often involves proceeding with in vitro fertilization without treating the endometrioma first, followed by surgery if needed (Miquel et al., 2020).
In addition to reproductive outcomes in patients affected by endometriosis, symptomatology and its consequent impact on quality of life have become highly relevant factors in treatment selection. Accordingly, specific pain scales and quality-of-life questionnaires have been developed to assess the impact on women affected by this condition. One such tool is the Endometriosis Health Profile scale, available in two versions (EHP-30 and EHP-5), designed by Dr. Stephen Kennedy and his team at the University of Oxford. It is a validated scale for assessing quality of life in patients with endometriosis and has been translated into nearly all languages (Jones et al., 2023; Bourdel et al., 2019).
The main objective of this project is to conduct a comparative analysis of patients diagnosed with ovarian endometrioma who undergo alcohol aspiration and sclerosis versus patients managed expectantly.
The outcomes to be evaluated include impact on quality of life, clinical improvement, pregnancy rate, and the need for subsequent surgery.
- Being tested
- Ultrasound-guided aspiration and alcohol sclerotherapy
- Medical subject headings
- Endometriosis, Pelvic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound-guided aspiration and alcohol sclerotherapyProcedure or surgery
Ultrasound-guided puncture and alcohol sclerotherapy
| Study group | Role | What they receive |
|---|---|---|
| Ultrasound-guided aspiration and alcohol sclerotherapy | Experimental | US-guided alcohol sclerotherapy of endometriomas with absolute etanol during 15 minutes, followed by a posterior wash. Receives: Procedure: Ultrasound-guided aspiration and alcohol sclerotherapy |
| Control group | No intervention | Expectant management with standard pain management if required |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Life of patients with endometrioma
Endometriosis Health Profile-5 (EHP-5), the minimum and maximum values (1-5), higher scores mean a worse outcome.
Measured: Baseline and at 6 months
Secondary outcomes (14)
Pelvic pain
Visual Analog Score for pain (dysmenorrhea), the minimum and maximum values (0-10), higher scores mean a worse outcome.
Measured: Baseline and at 6 months
Changes in pain-associated biomarkers 1
Blood: cortisol
Measured: Baseline and at 6 months
Changes in pain-associated biomarkers 2
Blood: CRP
Measured: Baseline and at 6 months
Changes in pain-associated biomarkers 3
Blood: IL-6
Measured: Baseline and at 6 months
Changes in pain-associated biomarkers 4
Urine: cortisol
Measured: Baseline and at 6 months
Changes in pain-associated biomarkers 5
Urine: adrenaline
Measured: Baseline and at 6 months
Changes in pain-associated biomarkers 6
Urine: noradrenaline
Measured: Baseline and at 6 months
Fertility preservation
Blood test: Antimullerian Hormone
Measured: Baseline and at 6 months
Antral follicle
Antral follicle count by US
Measured: Baseline and at 6 months
Pregnancy
Number of spontaneous pregnancies or pregnancies achieved through assisted reproductive techniques. Time to Conception
Measured: Through study completion, an average of 2 years
Reduction in cyst size
Largest diameter
Measured: Baseline and at 6 months
Adverse events and complications
Registered by Clavien-Dindo classification
Measured: Baseline and at 6 months
Misdiagnosed cysts
Number of patients with alternative diagnosis
Measured: During procedure
Healthcare costs
Direct and indirect treatment-related costs; cost-effectiveness analysis
Measured: Baseline to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2025
- Study start1 Jan 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for EndometriomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Model Description
- Masking
- None (open label)
- Enrolment
- 288 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Universitari de Bellvitge
- Sponsor type
- University, hospital or other
- Collaborators
- Carlos III Health Institute
- Responsible party
- Principal investigator, Amparo Garcia-Tejedor, Hospital Universitari de Bellvitge
- Investigators
- Amparo Garcia-Tejedor, MDPhD, Principal investigator, Hospital Universitari de Bellvitge
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06955221
- Sponsor's protocol ID
- PR 070/25
- Acronym
- ESCOMA
- Status last verified
- Oct 2026
- First submitted
- 8 Apr 2025
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Guevara-Peralta R, Martinez-Garcia JM, Ortega-Exposito C, Pla-Farnos MJ, Yeste C, Penafiel J, Guevara-Figueras J, Ponce J, Garcia-Tejedor A. Impact of ethanol sclerotherapy on pelvic pain and quality of life in patients with endometriomas (ESCOMA study): protocol for a randomised clinical trial. Front Reprod Health. 2026 Sep 10;8:1911200. doi: 10.3389/frph.2026.1911200. eCollection 2026.
PubMed 42787429
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of US-guided Alcohol Sclerotherapy for Endometriomas on Pelvic Pain and Quality of Life
- ClinicalTrials.gov ID
- NCT06955221
- Acronym / sponsor ID
- ESCOMA / PR 070/25
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 288 participants (estimated)
- Lead sponsor
- Hospital Universitari de BellvitgeUniversity, hospital or other
- Collaborators
- Carlos III Health Institute
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 2 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether ultrasound-guided alcohol sclerotherapy can improve pelvic pain and quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas, compared to expectant management.
The main questions it aims to answer are:
- - Does sclerotherapy significantly reduce pelvic pain compared to expectant management?
- - Does sclerotherapy improve quality of life as measured by the EHP-5 score?
Researchers will compare the sclerotherapy group to the expectant management group to determine whether the intervention leads to greater improvement in pain and quality of life.
Participants will:
- Be randomly assigned to one of two groups: (1) Sclerotherapy group: undergo ultrasound-guided puncture and alcohol sclerotherapy; (2) Control group: expectant management
- Complete quality of life and pain assessments at baseline and after 6 months
- Provide blood and urine samples for biomarker analysis (e.g., cortisol, IL-6, hsCRP, catecholamines)
- Undergo ovarian reserve assessments (AMH, antral follicle count)
- Be followed for adverse events, recurrence, fertility outcomes, and treatment-related costs
The study will follow an intention-to-treat and per-protocol analysis approach.
Detailed description
Endometriosis is a chronic gynecological disease that affects women of reproductive age, characterized by the abnormal growth of endometrial tissue outside the uterine cavity.
It affects 5-10% of women of reproductive age (Becker et al., 2022) and is associated with infertility in 40% of cases (Coccia et al., 2008). Among its clinical forms, ovarian endometrioma is the most frequent, appearing in 15-45% of patients with endometriosis (Cranney et al., 2017). In addition to its impact on fertility, the main clinical manifestation of endometriosis is pain. Chronic pelvic pain caused by endometriosis can be disabling and even lead to work absenteeism, with a significant impact on the quality of life of affected patients, who often experience delayed diagnosis, making its management even more difficult and requiring a multidisciplinary approach (Horne \& Missmer, 2022).
Currently, there is still no consensus on what should be the first-line treatment for ovarian endometrioma (Gordts \& Campo, 2019). However, cystectomy reduces ovarian reserve due to the removal of healthy ovarian tissue adjacent to the cyst wall-something that further worsens the reproductive prognosis in patients whose fertility is already diminished due to endometriosis per se (Alborzi et al., 2021; Martinez-Garcia et al., 2021). Moreover, despite surgical removal of the endometrioma, the recurrence rate is high, ranging from 15-30% (Jee, 2022).
In recent years, there has been a shift toward more conservative treatments for the management of endometrioma, such as expectant management or aspiration and sclerosis (Garcia-Tejedor et al., 2020). Various authors have shown that ultrasound-guided aspiration and alcohol sclerosis may be a promising option, as concluded in the meta-analysis by Cohen et al., which found that recurrence rates were similar to those of laparoscopic management of ovarian endometrioma, but with fewer complications. Results in assisted reproductive technology are also better compared to surgical treatment in symptomatic women, particularly in those with low ovarian reserve (Zhang et al., 2022). Furthermore, other comparative studies between surgery and aspiration-sclerosis have shown that, although recurrence rates are similar, pregnancy rates are higher in patients treated with sclerosis, with the same complication rate and significantly lower costs (Garcia-Tejedor et al., 2020; Zhang et al., 2022).
Currently, the first-line treatment in patients diagnosed with endometriosis is hormonal therapy through the use of hormonal contraceptives. However, its efficacy in managing endometrioma is lower, and therefore, there is no consensus on its indication for this specific form of endometriosis (Cranney et al., 2017). In patients with a desire for pregnancy, alternative approaches are sought that do not interfere with fertility. At present, this often involves proceeding with in vitro fertilization without treating the endometrioma first, followed by surgery if needed (Miquel et al., 2020).
In addition to reproductive outcomes in patients affected by endometriosis, symptomatology and its consequent impact on quality of life have become highly relevant factors in treatment selection. Accordingly, specific pain scales and quality-of-life questionnaires have been developed to assess the impact on women affected by this condition. One such tool is the Endometriosis Health Profile scale, available in two versions (EHP-30 and EHP-5), designed by Dr. Stephen Kennedy and his team at the University of Oxford. It is a validated scale for assessing quality of life in patients with endometriosis and has been translated into nearly all languages (Jones et al., 2023; Bourdel et al., 2019).
The main objective of this project is to conduct a comparative analysis of patients diagnosed with ovarian endometrioma who undergo alcohol aspiration and sclerosis versus patients managed expectantly.
The outcomes to be evaluated include impact on quality of life, clinical improvement, pregnancy rate, and the need for subsequent surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Model Description
| Arm | Type | Receives |
|---|---|---|
| Ultrasound-guided aspiration and alcohol sclerotherapy | Experimental | Procedure: Ultrasound-guided aspiration and alcohol sclerotherapyUS-guided alcohol sclerotherapy of endometriomas with absolute etanol during 15 minutes, followed by a posterior wash. |
| Control group | No intervention | –Expectant management with standard pain management if required |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Female sex
- Age ≥18 and ≤45 years
- Ultrasound suspicion of unilocular endometrioma or with a thin septum less than 3 mm
- Size between 30-100 mm, persistent for at least 3-6 months since diagnosis
- Ca125 marker <300 UI/mL and HE4 < 70 pM
Key exclusion criteria (9 listed)
- Age <18 or >45 years
- History of ovarian or uterine cancer
- Endometrioma size <30 mm or >100 mm
- Indication for surgical treatment of the endometrioma due to suspected severe extra-ovarian endometriosis or any other cause
- Ultrasound suspicion of dermoid cysts, anechoic cysts, or cysts with high risk of malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound-guided aspiration and alcohol sclerotherapyUltrasound-guided puncture and alcohol sclerotherapy | Procedure or surgery | Ultrasound-guided aspiration and alcohol sclerotherapy |
Primary outcome
Quality of Life of patients with endometrioma
Time frame: Baseline and at 6 months
Endometriosis Health Profile-5 (EHP-5), the minimum and maximum values (1-5), higher scores mean a worse outcome.
14 secondary outcomes
Pelvic pain
Time frame: Baseline and at 6 months
Changes in pain-associated biomarkers 1
Time frame: Baseline and at 6 months
Changes in pain-associated biomarkers 2
Time frame: Baseline and at 6 months
Changes in pain-associated biomarkers 3
Time frame: Baseline and at 6 months
Changes in pain-associated biomarkers 4
Time frame: Baseline and at 6 months
Changes in pain-associated biomarkers 5
Time frame: Baseline and at 6 months
Changes in pain-associated biomarkers 6
Time frame: Baseline and at 6 months
Fertility preservation
Time frame: Baseline and at 6 months
Antral follicle
Time frame: Baseline and at 6 months
Pregnancy
Time frame: Through study completion, an average of 2 years
Reduction in cyst size
Time frame: Baseline and at 6 months
Adverse events and complications
Time frame: Baseline and at 6 months
Misdiagnosed cysts
Time frame: During procedure
Healthcare costs
Time frame: Baseline to 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Derived from this study: PubMed 42787429Guevara-Peralta R, Martinez-Garcia JM, Ortega-Exposito C, Pla-Farnos MJ, Yeste C, Penafiel J, Guevara-Figueras J, Ponce J, Garcia-Tejedor A. Impact of ethanol sclerotherapy on pelvic pain and quality of life in patients with endometriomas (ESCOMA study): protocol for a randomised clinical trial. Front Reprod Health. 2026 Sep 10;8:1911200. doi: 10.3389/frph.2026.1911200. eCollection 2026.
- Individual participant dataSharing planned: No
Related trials for Endometrioma
RecruitingPhase 4
Estetrol/Drospirenone to Reduce the Average Size of Endometriomas
Ovarian Endometrioma, Endometrioma
Recruiting
Argon Plasma Treatment for Ovarian Endometrioma Compared to Standard Cystectomy
Endometriosis
RecruitingObservational study
Study on the Ultrasound and Biological Characteristics of Atypical Endometriosis.
Endometriosis
Not yet recruitingObservational study
Laparoscopic Sclerotherapy for the Management of Ovarian Endometriomas
Endometriosis, Endometrioma
RecruitingObservational study
Guangdong Provincial Endometriosis Clinical Research Cohort
Endometriosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amparo Garcia-Tejedor, MDPhD principal investigator
Hospital Universitari de Bellvitge
27 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ultrasound-guided aspiration and alcohol sclerotherapy in people with Endometrioma and Ultrasound Therapy; Complications, run by Hospital Universitari de Bellvitge at 27 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 27 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amparo Garcia-Tejedor, MDPhD (34 + 932607695 ext. 2812, agarciat@bellvitgehospital.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of Life of patients with endometrioma (time frame: Baseline and at 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06955221, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.